Researchers from Johns Hopkins University have highlighted that epigallocatechin gallate, a key component of green tea, may play a role in treating several gynecological conditions and could potentially improve success rates in assisted reproduction like IVF. These observations come from a review published in the journal Nutrients.
Among the antioxidant compounds found in green tea, EGCG stands out as a major active constituent. It has been extensively explored as a possible therapeutic agent in cancer research and is now being investigated for broader reproductive health applications.
The review synthesizes existing studies to explore how EGCG works at the cellular level and to assess its effectiveness in alleviating symptoms associated with benign female reproductive disorders.
Dysmenorrhea, marked by intense menstrual cramps, is linked to high prostaglandin levels produced in the uterus. Evidence suggests that EGCG can dampen the production of these inflammatory mediators and may offer an alternative to traditional NSAID therapies.
Across animal and human research, EGCG treatment has shown potential to shrink fibroids, which are non-cancerous uterine tumors, and to enhance overall well-being by easing related symptoms and improving daily functioning.
Endometriosis, characterized by the growth of uterine tissue outside its usual location, may also respond to EGCG. Studies in animal models indicate that EGCG can reduce existing endometrial lesions and may hinder the emergence of new growths.
Additionally, EGCG appears to support ovarian function by protecting eggs from oxidative damage, which can influence egg quality. If these protective effects translate clinically, they could influence IVF outcomes by improving the environment around egg fertilization and early embryo development.
Overall, the review indicates that EGCG has potential clinical benefits for benign gynecologic conditions, including polycystic ovary syndrome, endometriosis, dysmenorrhea, and fibroids. Nevertheless, the authors emphasize that robust clinical trials in humans are needed to validate these findings, since much of the current evidence derives from laboratory studies and animal models. [attribution: Nutrients journal study synthesis; needs human trials for confirmation.]